| Q27023393 | 18F-Labeled Peptides: The Future Is Bright |
| Q35082412 | Applications of Molecular Imaging |
| Q33870879 | Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease |
| Q53211169 | Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? |
| Q36621478 | Functional imaging of neuroendocrine tumours with PET. |
| Q57144951 | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
| Q40268569 | Nuclear medicine imaging and therapy of neuroendocrine tumours |
| Q37374442 | PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development |
| Q46969751 | PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions |
| Q33526620 | Peptide-based probes for targeted molecular imaging |
| Q33846924 | Peptides and peptide hormones for molecular imaging and disease diagnosis |
| Q39596344 | Radiolabeled peptides: valuable tools for the detection and treatment of cancer |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q95360903 | Somatostatin receptor PET ligands - the next generation for clinical practice |
| Q42548064 | Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors |
| Q27025187 | Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases |
| Q64238307 | The Search for an Alternative to [Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of F-labeled Somatostatin Analog Development |
| Q44462472 | Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography |
| Q53510437 | [Molecular imaging with new PET tracers]. |
| Q53363572 | [PET-CT for neuroendocrine tumors and nuclear medicine therapy options]. |